BioSpace News Archive

Chimeron Bio, an RNA company pioneering a novel class of mRNA-based vaccines and therapeutics is pleased to announce the appointment of Mr. Sven Otto Littorin as Head of its new Accessible Medicines Advisory Board (AMAB). AMAB is established to develop and execute strategies to make medicines developed by Chimeron Bio accessible to countries and its citizens worldwide.

Health Canada is warning Canadians about the risks of mixing bleach with other common household cleaning products, which can lead to the creation of toxic gases that can be poisonous if inhaled.

As COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.

Bristol Myers Squibb Receives European Commission Approval for Inrebic ® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis Inrebic, a once-daily, oral therapy, is the first new treatment option approved in Europe for myelofibrosis in nearly a decade

The following quote is attributed to Steven M. Solomon , D.V.M., M.P.H., director of the FDA’s Center for Veterinary Medicine: Veterinary regenerative medicine is a rapidly growing area of product development that offers great promise in the development of novel therapies for animals.

The U.S. Food and Drug Administration (FDA) has granted Vascular Perfusion Solutions, Inc. (VPS) a Breakthrough Device Designation for its groundbreaking VP.S Encore™ oxygenated perfusion cardiac transport device.

Radiology and pathology have been constantly undergoing transformation in terms of technology in the last few decades. Where radiology has evolved from films to digital images, pathology is also evolving from glass slides to digital imaging.

Increased number of research activities in all worldwide locations is projected to boost the expansion of the global polyclonal antibody market throughout the forecast period 2020–2030.

Quanterix Corporation announced the closing of its previously announced underwritten public offering of 4,107,142 shares of its common stock at a public offering price of $70.00 per share, including 535,714 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares.